Mizuho lowered the firm’s price target on Staar Surgical to $55 from $58 and keeps a Buy rating on the shares post the Q3 report. The company pointed toward macroeconomic pressures and a broad-based slowdown in the underlying refractive market as headwinds to growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STAA:
- Staar Surgical price target lowered to $40 from $45 at Piper Sandler
- Staar Surgical reports Q3 adjusted EPS 37c, consensus 18c
- STAA Earnings this Week: How Will it Perform?
- Staar Surgical price target lowered to $58 from $65 at Mizuho
- Fly Insider; STAAR Surgical, Blade Air among week’s notable insider trades